NasdaqGS:DERM

Stock Analysis Report

Executive Summary

Dermira, Inc., a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States.

Snowflake

Fundamentals

Adequate balance sheet with limited growth.


Similar Companies

Share Price & News

How has Dermira's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

25.8%

DERM

-0.06%

US Pharmaceuticals

0.4%

US Market


1 Year Return

-45.3%

DERM

-8.0%

US Pharmaceuticals

6.9%

US Market

Return vs Industry: DERM underperformed the US Pharmaceuticals industry which returned -8% over the past year.

Return vs Market: DERM underperformed the US Market which returned 6.9% over the past year.


Shareholder returns

DERMIndustryMarket
7 Day25.8%-0.06%0.4%
30 Day-13.2%-0.9%-1.1%
90 Day-16.1%-1.7%-0.5%
1 Year-45.3%-45.3%-5.8%-8.0%9.3%6.9%
3 Year-78.7%-78.7%18.3%10.0%45.8%36.4%
5 Year-52.5%-52.5%22.1%9.2%62.9%45.1%

Price Volatility Vs. Market

How volatile is Dermira's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Dermira undervalued compared to its fair value and its price relative to the market?

5.94x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate DERM's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate DERM's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: DERM is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: DERM is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate DERM's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: DERM is overvalued based on its PB Ratio (5.9x) compared to the US Pharmaceuticals industry average (2.9x).


Next Steps

Future Growth

How is Dermira forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

29.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: DERM is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: DERM is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: DERM is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: DERM's revenue (40.2% per year) is forecast to grow faster than the US market (7.2% per year).

High Growth Revenue: DERM's revenue (40.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if DERM's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Dermira performed over the past 5 years?

-39.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: DERM is unprofitable, and losses have increased over the past 5 years at a rate of -39.4% per year.

Accelerating Growth: Unable to compare DERM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DERM is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (24.3%).


Return on Equity

High ROE: DERM has a negative Return on Equity (-337.34%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: DERM is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: DERM is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Dermira's financial position?


Financial Position Analysis

Short Term Liabilities: DERM's short term assets ($428.5M) exceeds its short term liabilities ($50.9M)

Long Term Liabilities: DERM's short term assets (428.5M) exceeds its long term liabilities (330.8M)


Debt to Equity History and Analysis

Debt Level: DERM's debt to equity ratio (480.3%) is considered high

Reducing Debt: DERM's debt to equity ratio has increased from 4.1% to 480.3% over the past 5 years.


Balance Sheet

Inventory Level: DERM has a low level of unsold assets or inventory.

Debt Coverage by Assets: DERM's debt is covered by short term assets (assets are 1.360750x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: DERM has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: DERM has sufficient cash runway for 1.256368 years if free cash flow continues to reduce at historical rates of -54.6% each year.


Next Steps

Dividend

What is Dermira's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.8%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate DERM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate DERM's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if DERM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DERM's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DERM's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Dermira's salary, the management and board of directors tenure and is there insider trading?

5.6yrs

Average management tenure


CEO

Tom Wiggans (67yo)

9.2yrs

Tenure

US$4,371,178

Compensation

Mr. Thomas G. Wiggans, also known as Tom, co-founded Dermira, Inc. in August 2010 and has been its Chief Executive Officer since August 2010. Mr. Wiggans serves as an Advisor at Stiefel Laboratories. He ha ...


CEO Compensation Analysis

Compensation vs. Market: Tom's total compensation ($USD4.37M) is about average for companies of similar size in the US market ($USD1.79M).

Compensation vs Earnings: Tom's compensation has been consistent with company performance over the past year.


Management Age and Tenure

5.6yrs

Average Tenure

52yo

Average Age

Experienced Management: DERM's management team is seasoned and experienced (5.6 years average tenure).


Board Age and Tenure

5.5yrs

Average Tenure

60.5yo

Average Age

Experienced Board: DERM's board of directors are considered experienced (5.5 years average tenure).


Insider Trading

Insider Buying: DERM insiders have sold more shares than they have bought in the past 3 months.


Recent Insider Transactions

SellUS$52,63616 Sep 19
Matthew Fust
EntityIndividual
Role
Member of the Board of Directors
Non-Employee Director
Shares6,000
Max PriceUS$8.77
SellUS$169,45920 Aug 19
Luis Peña
EntityIndividual
Role
Top Key Executive
Co-Founder & Chief Development Officer
Shares19,843
Max PriceUS$8.54
BuyUS$199,99820 Aug 19
Thomas Wiggans
EntityIndividual
Role
Chief Executive Officer
Co-Founder
Shares23,419
Max PriceUS$8.54

Ownership Breakdown


Management Team

  • Tom Wiggans (67yo)

    Co-Founder

    • Tenure: 9.2yrs
    • Compensation: US$4.37m
  • Andrew Guggenhime (51yo)

    Chief Financial Officer

    • Tenure: 5.5yrs
    • Compensation: US$2.36m
  • Gene Bauer (77yo)

    Co-Founder

    • Tenure: 9.2yrs
    • Compensation: US$1.86m
  • Chris Griffith (43yo)

    Co-Founder and Chief Business & Strategy Officer

    • Tenure: 9.2yrs
    • Compensation: US$833.15k
  • Luis Peña (56yo)

    Co-Founder & Chief Development Officer

    • Tenure: 0yrs
    • Compensation: US$2.52m
  • Chris Horan (52yo)

    Chief Technical Operations Officer

    • Tenure: 1.5yrs
    • Compensation: US$2.36m
  • Christine Ring

    Vice President for Legal

    • Tenure: 5.2yrs
  • Lori Lyons-Williams (42yo)

    Chief Commercial Officer

    • Tenure: 2.8yrs
    • Compensation: US$2.70m
  • Mary Sillivos

    Vice President of Human Resources

    • Tenure: 5.8yrs
  • Erica Jefferson

    Vice President of Corporate Communications

    • Tenure: 0yrs

Board Members

  • Tom Wiggans (67yo)

    Co-Founder

    • Tenure: 9.2yrs
    • Compensation: US$4.37m
  • Fred Craves (73yo)

    Lead Independent Director

    • Tenure: 0yrs
    • Compensation: US$140.23k
  • Gene Bauer (77yo)

    Co-Founder

    • Tenure: 9.2yrs
    • Compensation: US$1.86m
  • Jake Nunn (49yo)

    Non-Employee Director

    • Tenure: 8.4yrs
    • Compensation: US$115.23k
  • Howard Maibach

    Scientific Advisor

    • Tenure: 0yrs
  • Matt Fust (54yo)

    Non-Employee Director

    • Tenure: 5.5yrs
    • Compensation: US$128.73k
  • Seth Orlow

    Scientific Advisor

    • Tenure: 0yrs
  • David Cohen (54yo)

    Non-Employee Director

    • Tenure: 5.3yrs
    • Compensation: US$133.73k
  • Brian Berman

    Scientific Advisor

    • Tenure: 0yrs
  • Sewon Kang

    Scientific Advisor

    • Tenure: 0yrs

Company Information

Dermira, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Dermira, Inc.
  • Ticker: DERM
  • Exchange: NasdaqGS
  • Founded: 2010
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$389.489m
  • Shares outstanding: 54.40m
  • Website: https://www.dermira.com

Number of Employees


Location

  • Dermira, Inc.
  • 275 Middlefield Road
  • Suite 150
  • Menlo Park
  • California
  • 94025
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
DERMNasdaqGS (Nasdaq Global Select)YesCommon SharesUSUSDOct 2014
19DDB (Deutsche Boerse AG)YesCommon SharesDEEUROct 2014

Biography

Dermira, Inc., a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholiner ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/20 00:38
End of Day Share Price2019/10/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.